It is hypothesised that the reduced toxicity is due to the selective activity against PD-1/PD-L1 signalling as PD-1/PD-L2 signalling is also attenuated by anti-PD-1, which increases treatment-induced autoimmunity [39,40]. The gene discussed is PDCD1LG2; the disease is Autoimmunity.